Robert Besthof, M.I.M.
Interim CEO, Head of Operations & Chief Commercial Officer
Mr. Besthof is a global biopharmaceutical executive with a 25+ year career covering global pipeline & country operational marketing & sales roles. He has managed numerous specialty diseases areas, including small as well as billion-dollar brands in Ophthalmology, Neuroscience, Pain, and Pulmonary Vascular Disease. His teams have played key roles in translating new science into investable commercial paths, reshaping markets, launching breakthrough products, and closing numerous licensing deals. Mr. Besthof has worked for Eli Lilly, Wyeth, and most recently Pfizer, as Vice President Commercial Development Neuroscience & Pain. Earlier in his career he worked for Deutsche Band and for various consulting firms. He holds a B.A. from Case Western Reserve University and a master’s in international management from the Thunderbird School of Global Management.
Chief Financial Officer and Treasurer
Mr. Strassberg brings with him more than thirty years finance and accounting experience and has served as Deputy Chief Financial Officer at Cantor Fitzgerald, L.P. and Chief Financial Officer at Cantor Commercial Real Estate Company. Mr. Strassberg also served on the Board of Directors of Continental Building Products, Inc. Earlier in his career, Mr. Strassberg served as Chief Financial Officer of Berkeley Point Capital, Fannie Mae's multifamily business division, and Walker & Dunlop. He also held senior roles in both audit and consulting at KPMG, where he had direct experience in complex commercial transactions. Mr. Strassberg, who earned his B.S. in Accounting from Georgetown University, is a Certified Public Accountant, a Certified Management Accountant, and a Chartered Global Management Accountant.
General Counsel & Secretary
Mrs. Daigneault joined NRx as its Corporate Secretary in September 2020. Prior to joining NRx, she was co-founder and Chief Operating Officer of Quantum Governance LLC, where she continues to serve as a director. She also served as Vice President and Chief Legal Counsel for Teligent, Inc. and its successor companies, First Avenue Networks and FiberTower Corporation, all publicly traded telecommunications companies, from October 2000 to May 2008. Ms. Daigneault began her legal career with Milbank LLP and was a Partner at the Washington, D.C. law firm of Tucker, Flyer & Lewis (now Venable LLP) where she represented clients on various corporate and commercial transactions. Ms. Daigneault holds a Bachelor of Science, Magna Cum Laude, from Georgetown University and a Juris Doctor from Georgetown University Law Center.
Chief Business Officer
Randy brings over 30 years of investment banking experience dedicated to advising biopharmaceutical companies worldwide. He has advised on numerous corporate M&A, partnering transactions and public and private financings. Most recently, Randy was a Managing Director at Young & Partners, a boutique investment banking firm serving the life sciences and chemical industries. Prior to Young & Partners, Randy was Head of Health Care Investment Banking for the Americas at Dresdner Kleinwort Wasserstein and worked for over 15 years at Lehman Brothers as Managing Director in the Healthcare Group, Managing Director in the Mergers and Acquisitions Group and as Co-Head of Healthcare Mergers & Acquisitions.
Randy received an AB degree in Economics at Harvard College and earned an MBA from Harvard Business School.
Philip T. Lavin, PH.D.
Dr. Lavin is a highly respected biostatistician with more than 30 years of experience supporting the design and analysis of clinical trials. Previously, he was a member of the biostatistics faculty at the Harvard School of Public Health and a member of the Department of Surgery at Harvard Medical School where he was affiliated for over 25 years. He co-founded Boston Biostatistics in 1983, a company known as Aptiv Solutions. During his career, Dr. Lavin has served as lead biostatistician for 50 FDA approvals, including 38 PMAs, more to date than any other biostatistician. He has also served as a Special Government Employee for 30 years where he has advised the FDA on complex statistical and policy issues.
Dennis K. McBride, PH.D.
Chief Strategy Officer & Senior Scientist
Dr. McBride has led numerous national and international initiatives in neuroscience and its interface with information technology, national security, and medical technology/drug development within the federal government, three of which are now multi-billion dollar enterprises. He began his career as a medical scientist in Naval Aviation and ergonomics and served in eight nationally prominent laboratories and headquarters organizations, including the Defense Advanced Research Projects Agency (DARPA), Naval Aerospace Medical Research Lab, Naval Research Lab, the Office of Naval Research, and the Naval Medical Research Institute. Upon retiring as a highly decorated senior officer (O-6), he assumed the leadership of the Potomac Institute for Policy Studies, which he continues to serve as President Emeritus. Following his ten-year term, he was recruited back to the National Defense University to lead the Center for Technology and National Security Policy, culminating his government career there as Senior Executive-4 (Civilian equivalent to Rear Admiral/Vice Admiral).
Dennis has served as adviser to Cabinet Secretaries, congressional committees, and to major corporate C-Suite executives. His educational background includes formal enrollment at the University of Georgia, Naval Aerospace Medical Institute (Flight Surgeon School), the University of Southern California, the London School of Economics, and Harvard Business School, with the award of the Ph.D. in experimental psychology, four master’s degrees, and additional postdoctoral education in aviation medicine, systems engineering science, and strategic disruption. He has published widely, was elected by faculty in 1999 to full professor, and has served at multiple universities, full- and part-time in colleges of Arts & Sciences, Engineering, Public Policy, and Medicine. For the past 12 years, Dr. McBride has served as adjunct professor at Georgetown University School of Medicine and co-Director of Georgetown’s Regulatory Science Program.
Regulatory & Patient Advocacy Adviser
Mr. Pines previously served as Associate Commissioner of the US Food and Drug Administration.
Harry B. Peled, M.D. FACC, CCS, CCS-P, HEC-C
Clinical Advisor COVID-19
Dr. Harry Peled is the Medical Director of Cardiology and Critical Care at Saint Jude medical center in Fullerton, California. In addition to being board-certified in cardiology and critical care, he is also board-certified in geriatrics, palliative care, and Neurocritical care. He graduated from Albert Einstein College of Medicine with special distinction for research. He has authored work published In the New England Journal of Medicine, Chest, Annals of internal medicine, and many others. He also holds a master's in bioethics and health policy from Loyola University.
Melvin L. Morganroth, M.D.
Clinical Advisor COVID-19
Dr. Morganroth received both his undergraduate degree and medical degree from the University of Michigan in Ann Arbor. He is completing both his internship and residency in Internal Medicine at Yale University School of Medicine. He completed a Pulmonary and Critical Care Fellowship at the University of Colorado Health Sciences Center in Denver. He was an Assistant Professor at the University of Michigan in the Pulmonary and Critical Care Division from 1984-1990. At the University of Michigan, in addition to being active in patient care, he was also director of the Critical Care Medicine Unit, co-director of the critical care fellowship training program and carried out basic research on acute lung injury. Since 1990 he has been the director of the research department in the Pulmonary, Critical Care and Sleep Division of The Oregon Clinic. He is active in patient care, teaching and clinical research. He has been the principal investigator in many research studies and authored multiple journal articles and book chapters on topics related to respiratory disease.
Jonathan C. Javitt, M.D., M.P.H.
Founder & Chief Scientist
Dr. Javitt has played leadership roles in seven successful healthcare IT and biopharma startups with public exits. He has additionally led drug-development engagements for Merck, Allergan, Pharmacia, Novartis, and Pfizer. He was appointed to healthcare leadership roles under Presidents Reagan, George H.W. Bush, Clinton, and George W. Bush. In the latter role he was commissioned to lead the White House policy for universal adoption of Health IT and establishment of the Office of the National Coordinator. He is a graduate of Princeton University, Cornell University Medical College, Harvard School of Public Health, the Wills Eye Hospital, and Johns Hopkins Medical School. Dr. Javitt has published more than 200 scientific works in the areas of health outcomes and Pharmacoeconomics that have been cited by more than 16,000 people. In his role as Chief Scientist of NRx Pharmaceuticals he continues to support NRx on Scientific matters to advance and expand our pipeline.
Prof. Daniel C. Javitt, M.D., Ph.D.
Co-founder & Chair, Scientific Advisory Board
Professor Javitt has devoted the past 30 years to the intersection of psychiatry and brain science. He was the first to identify the role of the NMDA receptor in modulating human thought processes in psycho-affective disorders. He is the author of more than 250 scientific publications and 10 patents in the field and is one of the most-widely cited authors in neuropsychiatry. His work has merited awards from the American Psychiatric Association and other leading organizations.